Hit enter to search or ESC to close
YOZMA GROUP KOREAYOZMA GROUP KOREA
Menu
  • About
    • Overview
    • Our Team
  • Business
    • Investment
    • Accelerator
    • Consulting
    • Tech Transfer
  • Campus
    • Overview
    • Partners
    • Portfolio
  • Portfolio
  • Newsroom
    • News
    • Press Release
    • Video
  • Contact
    • Recruit
  • English
    • Korean
  • About
    • Overview
    • Our Team
  • Business
    • Investment
    • Accelerator
    • Consulting
    • Tech Transfer
  • Campus
    • Overview
    • Partners
    • Portfolio
  • Portfolio
  • Newsroom
    • News
    • Press Release
    • Video
  • Contact
    • Recruit
  • English
    • Korean
Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days
News

Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days

By 관리정경단2022-06-02June 27th, 2022No Comments

Home » Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days

Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days

https://www.proactiveinvestors.com/companies/news/983880/todos-medical-says-dietary-supplement-tollovid-has-beneficial-effect-in-long-covid-case-study-after-26-days-983880.html
  • Previous Post"Government should invest in early technology in order to build strong startup ecosystem"

  • Next Post"Reduce charging time." What are the reasons Polstar investing in battery technology company 'Storedot'?

Seoul Office
9F, 457, Bongeunsa-ro, Gangnam-gu, Seoul, Republic of Korea
t. +82 2 6949 5350
e. [email protected]

Israel Office
2 Ben Gurion way, BSR 1 building fl 14, Ramat Gan, Israel
e. [email protected]

Family Site →
  • Privacy Policy

© 2025 Yozma Group Korea.